Belite Bio, Inc (BLTE): Insider Trading, Congress Trades & Research | Tormere

BLTE

$159.56-2.10%website ↗⬇ financials (.py)

BELITE BIO, INC

Market Cap

$6.4B

Live price × shares (2026-09-16)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

-1.19

53mo monthly vs SPY

P/E (TTM)

—

Price / TTM net income

P/S (TTM)

—

Price / TTM revenue

P/B

8.3

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

14 analysts

Velocity Score

36.60x

Sell Rate (90d)

1931.59/mo

Sell Baseline

135.37/mo

Unique Sellers (90d)

3

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-08	2026-09-09	Lin Yu-Hsin	Director & Chief Executive Officer	Sale	26.0K	$196.56	$5.11M	70.1K	View
2026-09-08	2026-09-09	Chuang Hao-Yuan	Director & Chief Financial Officer	Sale	18.0K	$196.42	$3.53M	26.0K	View
2026-09-04	2026-09-09	Chuang Hao-Yuan	Director & Chief Financial Officer	Sale	41.2K	$187.37	$7.73M	44.0K	View
2026-09-04	2026-09-09	Lin Yu-Hsin	Director & Chief Executive Officer	Sale	68.2K	$187.75	$12.81M	96.1K	View
2026-08-12	2026-08-14	Lin Yu-Hsin	Director & Chief Executive Officer	Sale	365	$180.35	$66K	170.6K	View

1–5 of 28

1 / 6

Reporting Insiders

Recent News

4,000 Belite Bio (BLTE) depositary shares are proposed for sale, valued at $679K.

Stock Titan · 2026-10-01

Belite Bio (BLTE) Draws Fresh Valuation Attention After FDA Priority Review And Euretina Spotlight

Simply Wall Street · 2026-10-01

Belite Bio, Inc (BLTE) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-10-01

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Yahoo · 2026-10-01

Doctors will present 24-month results from a teen eye-disease trial in New Orleans.

Stock Titan · 2026-10-01

Belite Bio (BLTE) 10K Form and Latest SEC Filings 2026

MarketBeat · 2026-10-01

How (BLTE) Movements Inform Risk Allocation Models

news.stocktradersdaily.com · 2026-09-30

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SeekingAlpha · 2026-09-14

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

Yahoo · 2026-09-09

Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Benzinga · 2026-09-09

Belite Bio On Track For A Potential Blockbuster Launch In 2027

SeekingAlpha · 2026-09-09

HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Benzinga · 2026-09-08

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

Yahoo · 2026-09-08

Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1

Benzinga · 2026-09-08

UiPath downgraded, Shell upgraded: Wall Street's top analyst calls

Yahoo · 2026-09-04

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-09-08	Lin Yu-Hsin	S	2,700	$534,844.89
2026-09-08	Chuang Hao-Yuan	S	2,200	$427,414.02
2026-09-08	Chuang Hao-Yuan	S	4,120	$805,888.89
2026-09-08	Chuang Hao-Yuan	S	4,475	$879,199.67
2026-09-08	Chuang Hao-Yuan	S	4,605	$908,243.69